ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1457

Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis

Romina Nieto1, Rosana Quintana2, eduardo Borba3, Lucia Hernandez4, Diana Fernandez-Avila5, Laura Maurelli6, Paul Alba7, Florencia Bordon8, Fernando Arizpe9, Guillermo Berbotta10, Rosa Serrano-Morales11, Maria Constanza Bertolaccini12, Eduardo Kerzberg13, Maria Angeles Gargiulo14, Anabella Rodriguez15, Vitalina Barbosa16, Andres gasparin17, Fernando Cavalcanti18, Laissa Alves Alvino19, Luciana Parente Costa Seguro20, Lucas Victoria de Oliveira Martins21, oscar Niera22, Loreto Massardo23, Gustavo Aroca Martinez24, Ivana Nieto Aristizabal25, Paul Mendez Patarroyo26, Antonio iglesias Gamarra24, Andres Zuniga Vera27, Olga-Lidia Vera-Lastra28, Mario Perez Cristobal29, Eduardo Martin-Nares30, Luis M Amezcua-Guerra31, Yelitza Gonzalez-Bello32, Octavio Gonzalez Enriquez33, Dionico Galarzo-Delgado34, Carolina Vazquez35, Marcelo barrios36, Magaly Alba Linares37, Cristina Reategui38, Ana Quiroz-Alva39, Teresandris Polanco Mora40, Carina Pizzarossa41, Martin Rebella42, Maria Crespo43, Alvaro Danza44, Eloisa Silva Dutra de Oliveira Bonfa45, Graciela Alarcón46, Federico Zazzetti47, Ashley Orillion48, Guillermo Pons-Estel49 and Urbano Sbarigia50 1GO-CREAR, Rosario, Santa Fe, Argentina, 2Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, 4Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, 5Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 6Hospital Italiano de Córdoba, Córdoba, Argentina, 7Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 9Hospital HIGA San Martín, San Martín, Argentina, 10Sanatorio Británico, Rosario, Argentina, 11Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, 12Hospital Padilla, San Miguel de Tucuman, Argentina, 13Hospital General de Agudos Dr. Ramos Mejia, Buenos Aires, Argentina, 14Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, 15CEMIC, Galvan, Argentina, 16Universidade Federal de Goiás, Goiana, Brazil, 17Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 18Universidad Federal de Pernambuco, Recife, Brazil, 19Hospital Universitario Pedro Ernesto, UERJ, Rio de Janiero, Brazil, 20Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 21Universidad Federal São Paulo, São Paulo, Brazil, 22Hospital del Salvador, Providencia, Chile, 23Universidad San Sebastián, Santiago de Chile, Chile, 24Clínica de la Costa Ltda., Barranquilla, Colombia, 25Fundación Valle del Lili, Calí, Colombia, 26Fundación Santa Fe, Bogotá, Colombia, 27Hospital Luis Vernaza, Guayaquil, Ecuador, 28Centro Médico La Raza, Ciudad de México, Mexico, 29Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, 30Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 31Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 32Centro de Estudios de investigación Básica y Clínica S.C, Jalisco, Mexico, 33Hospital Central Dr. Ignacio Morones Prieto, San Luis, Mexico, 34Hospital Universitario "Dr. José Eleuterio Gonzalez", Monterrey, Mexico, 35Hospital de Clínicas I, Montevideo, Uruguay, 36Hospital de Clínicas II, Montevideo, Uruguay, 37Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 38Hospital Nacional Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 39Hospital Cayetano Heredia, San Martín de Porres District, Peru, 40Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, 41Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, 42Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, 43Hospital Señor del Milagro, Salta, Argentina, 44Grupo de Investigacion de EAIS y Reumatológicas, A Coruña, Spain, 45Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 46The University of Alabama at Birmingham, Oakland, 47Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, 48Janssen, Horsham, PA, 49CREAR, Rosario, Argentina, 50Johnson & Johnson, Beerse, Belgium

Meeting: ACR Convergence 2022

Keywords:

Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Clinically evident kidney disease eventually occurs in up to one-half of SLE patients. The aim of this study is to describe sociodemographic, clinical, serological and treatment characteristics of a multicenter and multiethnic Latin American SLE cohort (GLADEL 2.0. Grupo Latino Americano De Estudio del Lupus) of patients with or without lupus nephritis (LN).

Methods: The GLADEL 2.0 is an observational prevalent and incident cohort initiated in 2019. Forty-four centers from 10 Latin-American countries enrolled patients ≥18 years who fulfilled 1982/1997 American College of Rheumatology (ACR) classification criteria for SLE. Patients of this cohort were categorized into four different subsets: Group I: Without renal involvement (never); Group II: With prevalent renal involvement. currently inactive; Group III: With prevalent renal involvement. currently active. and Group IV: With incident renal (onset < 3 months) involvement with renal biopsy. Demographic, clinical manifestations, treatments, disease activity (SLEDAI- 2k) and SLICC/ACR Damage Index (SDI) were examined at baseline. A descriptive cross-sectional analysis of data collected from May 2019 to May 2022 was performed. Numeric variables are reported as medians (interquartile ranges IQR) and compared using Kruskall-Wallis test; categorical variables are reported as frequencies (percentages) and compared using Chi-square or Fisher tests, as appropriate.

Results: A total of 991 SLE patients were included. 884 (89.2%) were female. Median (IQR) age at cohort entry was 35 (28-45) years. Median disease duration was 67 months (18-139) and 656 (68.3%) were Mestizos (of Amerindian and European ancestry). Patients with incident LN (group IV) had a higher proportion of males, were younger at diagnosis, had a shorter disease duration and were more frequently Mestizos (Table 1). Clinical, serological, treatment, disease activity and damage among groups are noted in Table 2, and revealed that for group I pericarditis and anti-dsDNA were less frequent and MMF was less often used by group I and IV. Table 3 shows the renal characteristics of the 510 patients (349 patients with prevalent LN from group II and III and 161 incident LN patients from Group IV) who underwent a kidney biopsy with a clear predominance of Class IV.

Conclusion: Baseline characteristics of the GLADEL 2.0 well characterized lupus patients’ cohort with or without LN are described with distinct demographic, clinical and laboratory patterns that will allow both centralized laboratory evaluation of urinary biomarkers and exploratory biomarker analyses including transcriptome and their impact on the outcome of these patients.

Supporting image 1

Table 1: GLADEL 2.0 Sociodemographic Characteristics

Supporting image 2

Table 2: Clinical characteristics, disease activity, damage index and treatment at cohort entry.

Supporting image 3

Table 3: Renal characteristics of patients with LN proven by renal biopsy.

Disclosures: R. Nieto, None; R. Quintana, None; e. Borba, None; L. Hernandez, None; D. Fernandez-Avila, None; L. Maurelli, None; P. Alba, Pfizer, AbbVie/Abbott, Elea Phoenix, International League of Associations of Rheumatology; F. Bordon, None; F. Arizpe, None; G. Berbotta, None; R. Serrano-Morales, Pfizer, AbbVie/Abbott, Elea Phoenix, International League of Associations of Rheumatology; M. Bertolaccini, None; E. Kerzberg, None; M. Angeles Gargiulo, None; A. Rodriguez, None; V. Barbosa, None; A. gasparin, None; F. Cavalcanti, None; L. Alves Alvino, None; L. Parente Costa Seguro, None; L. Victoria de Oliveira Martins, None; o. Niera, None; L. Massardo, None; G. Aroca Martinez, None; I. Nieto Aristizabal, None; P. Mendez Patarroyo, None; A. iglesias Gamarra, None; A. Zuniga Vera, None; O. Vera-Lastra, None; M. Perez Cristobal, None; E. Martin-Nares, None; L. Amezcua-Guerra, None; Y. Gonzalez-Bello, None; O. Gonzalez Enriquez, None; D. Galarzo-Delgado, None; C. Vazquez, None; M. barrios, None; M. Alba Linares, None; C. Reategui, Janssen; A. Quiroz-Alva, None; T. Polanco Mora, None; C. Pizzarossa, None; M. Rebella, AbbVie, Bayer, Pfizer, Roche; M. Crespo, None; A. Danza, None; E. Silva Dutra de Oliveira Bonfa, None; G. Alarcón, None; F. Zazzetti, Janssen Medical Affairs Global Services, LLC; A. Orillion, Janssen; G. Pons-Estel, Janssen, GSK, Pfizer, Werfen/Inova, Novartis; U. Sbarigia, Janssen.

To cite this abstract in AMA style:

Nieto R, Quintana R, Borba e, Hernandez L, Fernandez-Avila D, Maurelli L, Alba P, Bordon F, Arizpe F, Berbotta G, Serrano-Morales R, Bertolaccini M, Kerzberg E, Angeles Gargiulo M, Rodriguez A, Barbosa V, gasparin A, Cavalcanti F, Alves Alvino L, Parente Costa Seguro L, Victoria de Oliveira Martins L, Niera o, Massardo L, Aroca Martinez G, Nieto Aristizabal I, Mendez Patarroyo P, iglesias Gamarra A, Zuniga Vera A, Vera-Lastra O, Perez Cristobal M, Martin-Nares E, Amezcua-Guerra L, Gonzalez-Bello Y, Gonzalez Enriquez O, Galarzo-Delgado D, Vazquez C, barrios M, Alba Linares M, Reategui C, Quiroz-Alva A, Polanco Mora T, Pizzarossa C, Rebella M, Crespo M, Danza A, Silva Dutra de Oliveira Bonfa E, Alarcón G, Zazzetti F, Orillion A, Pons-Estel G, Sbarigia U. Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/baseline-characteristics-of-a-longitudinal-multinational-multiethnic-study-of-lupus-patients-with-or-without-lupus-nephritis/. Accessed .

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-characteristics-of-a-longitudinal-multinational-multiethnic-study-of-lupus-patients-with-or-without-lupus-nephritis/